Strategies to Enhance the Distribution of Therapeutic Nanoparticles in the Brain by Convection Enhanced Delivery

Negron, Karina; Khalasawi, Namir; Suk, Jung Soo

doi:10.1007/978-1-0716-1052-7_7

Cited by 3 publications

(2 citation statements)

References 120 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The CED is an intracranial administration method clinically employed to enhance the therapeutic distribution within the brain by creating a continuous pressure-driven bulk flow. [22][23][24] The brain tissues were immediately harvested upon the completion of the administration for the assessment of the volumetric distribution of NPs. Representative confocal images of the coronal plane at the administration site showed that particle distribution was enhanced by all three poloxamer coatings (Figure 2A).…”

Section: Distribution Of Various Poloxamer-coated Plga Nps In Healthy...mentioning

confidence: 99%

A Highly Translatable Dual‐arm Local Delivery Strategy To Achieve Widespread Therapeutic Coverage in Healthy and Tumor‐bearing Brain Tissues

Negron

Kwak

Wang

et al. 2023

Small

Self Cite

View full text Add to dashboard Cite

Drug delivery nanoparticles (NPs) based entirely on materials generally recognized as safe that provide widespread parenchymal distribution following intracranial administration via convection‐enhanced delivery (CED) are introduced. Poly(lactic‐co‐glycolic acid) (PLGA) NPs are coated with various poloxamers, including F68, F98, or F127, via physical adsorption to render particle surfaces non‐adhesive, thereby resisting interactions with brain extracellular matrix. F127‐coated PLGA (F127/PLGA) NPs provide markedly greater distribution in healthy rat brains compared to uncoated NPs and widespread coverage in orthotopically‐established brain tumors. Distribution analysis of variously‐sized F127/PLGA NPs determines the average rat brain tissue porosity to be between 135 and 170 nm while revealing unprecedented brain coverage of larger F127/PLGA NPs with an aid of hydraulic pressure provided by CED. Importantly, F127/PLGA NPs can be lyophilized for long‐term storage without compromising their ability to penetrate the brain tissue. Further, 65‐ and 200‐nm F127/PLGA NPs lyophilized‐reconstituted and administered in a moderately hyperosmolar infusate solution show further enhance particle dissemination in the brain via osmotically‐driven enlargement of the brain tissue porosity. Combination of F127/PLGA NPs and osmotic tissue modulation provides a means with a clear regulatory path to maximize the brain distribution of large NPs that enable greater drug loading and prolong drug release.

show abstract

Section: Distribution Of Various Poloxamer-coated Plga Nps In Healthy...mentioning

confidence: 99%

A Highly Translatable Dual‐arm Local Delivery Strategy To Achieve Widespread Therapeutic Coverage in Healthy and Tumor‐bearing Brain Tissues

Negron

Kwak

Wang

et al. 2023

Small

Self Cite

View full text Add to dashboard Cite

show abstract

“…Future advances will involve developing therapeutic agents for delivery via CED, and improving the technique [ 32 ]. In this context, nanotechnology-based delivery systems designed for use with CED could be of aid [ 34 ]. Despite this, it turns out to be an invasive and technically challenging solution.…”

Section: Introductionmentioning

confidence: 99%

Nanoparticles for Diagnosis and Target Therapy in Pediatric Brain Cancers

et al. 2022

View full text Add to dashboard Cite

Pediatric brain tumors represent the most common types of childhood cancer and novel diagnostic and therapeutic solutions are urgently needed. The gold standard treatment option for brain cancers in children, as in adults, is tumor resection followed by radio- and chemotherapy, but with discouraging therapeutic results. In particular, the last two treatments are often associated to significant neurotoxicity in the developing brain of a child, with resulting disabilities such as cognitive problems, neuroendocrine, and neurosensory dysfunctions/deficits. Nanoparticles have been increasingly and thoroughly investigated as they show great promises as diagnostic tools and vectors for gene/drug therapy for pediatric brain cancer due to their ability to cross the blood–brain barrier. In this review we will discuss the developments of nanoparticle-based strategies as novel precision nanomedicine tools for diagnosis and therapy in pediatric brain cancers, with a particular focus on targeting strategies to overcome the main physiological obstacles that are represented by blood–brain barrier.

show abstract

Precision drug delivery to the central nervous system using engineered nanoparticles

Gao,

Xia,

Gunasekar

et al. 2024

Nat Rev Mater

View full text Add to dashboard Cite

Strategies to Enhance the Distribution of Therapeutic Nanoparticles in the Brain by Convection Enhanced Delivery

Cited by 3 publications

References 120 publications

A Highly Translatable Dual‐arm Local Delivery Strategy To Achieve Widespread Therapeutic Coverage in Healthy and Tumor‐bearing Brain Tissues

A Highly Translatable Dual‐arm Local Delivery Strategy To Achieve Widespread Therapeutic Coverage in Healthy and Tumor‐bearing Brain Tissues

Nanoparticles for Diagnosis and Target Therapy in Pediatric Brain Cancers

Precision drug delivery to the central nervous system using engineered nanoparticles

Contact Info

Product

Resources

About